Key Takeaways
- Turnaround quarter, volume-led: Revenue rebounded sharply on a near-doubling of Vizag capacity utilization, with pricing broadly stable. The jump added ₹30–40 crore of absolute gross margin despite a slight percentage dip.
- Vizag under-recoveries halved: The drag from the Vizag plant fell from ₹40 crores to ₹10 crores in H1 as ibuprofen utilization climbed from ~20–25% to 50% or higher. Full utilization and a broader product mix are still some time away.
- Ibuprofen demand stable, not surging: Management sees demand stability over the next 2–3 years based on customer discussions, with some pricing pressure but no corrective price cuts. The strategy is to reduce percentage dependence on ibuprofen while growing absolute market share.
- Rights issue on a fast track: Work is ongoing in the background and management expects to announce the plan within the current quarter.
- What to watch next quarter: Whether the rights issue is actually announced, the quantum of impact from the Pondicherry fire, any progress on debtors (currently >90 days), and if the revenue step-up holds.
Topline Recovery & Volume Dynamics
- Revenue jump driven by utilization: Robust review mechanisms to extract maximum value from current assets were the primary reason for growth, with demand recovery across the product basket and a strong strategic focus on Vizag utilization.
- Volume, not price: Revenue growth was broadly volume-driven due to increased Vizag utilization. Pricing was broadly stable with no corrective measures or price reductions taken.
- Regulated markets dominate: 70% of revenue came from regulated markets. Traction was driven not only by ibuprofen but also by other products improving capacity utilization in other plants.
- Sustainability bet: Management aspires to maintain current revenue levels, citing stability in demand, ongoing customer engagement, and strong fundamentals. The ibuprofen demand increase this quarter is not seen as temporary; the company was first to launch ibuprofen in China and is entering new markets.
Purohit: "Q2 2024 is a turnaround quarter for Solara with improved capacity utilization."
Vizag: The Central Lever
- Utilization leap: Capacity utilization at Vizag moved from ~20–25% to 50% or higher, halving under-recoveries from ₹40 crores to ₹10 crores for H1. The plant is majorly dedicated to ibuprofen (two-thirds of capacity), with separate blocks identified for 4–5 other products.
- Revenue vs potential gap explained: The ₹33 crores revenue this quarter versus the ₹400 crores potential reflects that only one dedicated block (ibuprofen) has been commissioned and utilized. Several other products were not scaled up; full capacity utilization requires all products together, and a product mix change may be needed for optimum revenue.
- Path to full utilization: Qualifying other customers and entering new markets are the levers to drive utilization further. The high-KL capacity plant is looking at high-volume products.
- Conservative upside: Per an analyst's math, 100% utilization could add ₹50–60 crores minimum turnover and ₹20–30 crores margin. Management called this "definitely doable on a conservative basis" but said it is looking at much bigger plans.
Margin & Cost Structure
- Gross margin dip is mechanical, not alarming: Gross margin fell from 45.5% to 44.3% QoQ, explained by the steep revenue jump back to old levels. When not fully utilized, under-recoveries affect gross margin. Management advocates looking at a moving annual total basis and notes that maintaining the same gross margin while increasing revenue significantly added ₹30–40 crore of absolute gross margin, which flows to the bottom line.
- EBITDA margin ambition: The stated objective is to reach higher-teens EBITDA margins, with corrective steps being taken one at a time. Displaying sequential growth quarter on quarter is seen as very important to this path.
- Gross margin target: Management expects gross margin to return to the 50% historic level consistently in the next 2–3 years, driven by backward integration and in-house production of some steps on molecules where the company is not fully backward integrated.
- OPEX under review: Other expenses rose ~₹20 crores YoY partly due to lower Vizag utilization. Management acknowledges OPEX is high and plans to benchmark with industry to bring costs down, though not immediately next quarter.
Purohit: "if I'm able to maintain the same gross margin and increase the revenue growth significantly that adds to absolute gross margin, you see a 30 crore, 40 crore of jump of gross margin which actually adds to the bottom line only."
Ibuprofen: Dependence & Strategy
- Demand stable, not rising: Ibuprofen prices have remained stable, not gone up. The company is trying to secure long-term engagements with premium customers so price fluctuations do not affect them. Over the next 2–3 years, based on customer discussions, demand is expected to be stable in a range, with some pricing pressure considered normal.
- Deliberate diversification: The objective is to reduce percentage dependence on ibuprofen (historically 45–50%) while increasing absolute market share. Other products must grow significantly so the percentage comes down as absolute contributions from other products grow.
- New products not yet quantified: Management declined to quantify new products' contribution, saying it is difficult at this stage, with an optimistic estimate of 18–24 months. Work is ongoing on gross margin, revenue, and EBITDA margin from these products.
Purohit: "Our objective would be to reduce the percentage of dependence while also increasing the market share in absolute terms. So, basically which means the other products also have to grow significantly"
Balance Sheet & Cash Flow
- Debt trending down slowly: Gross debt stood at ₹972 crores as of September-end, with a reduction of ₹29 crores between March and September. Management is directionally looking at further reducing debt but gave no specific year-end target.
- Debtors elevated: Debtors are high relative to turnover at more than 90 days. Management acknowledges this and expects improvement as a function of business activities and measures taken.
- Cash flow visibility withheld: Management declined to give a stable operating cash flow number, saying only that cash flow will improve with business growth and improved balance sheet hygiene.
- Rights issue imminent: Work is ongoing in the background and has taken some time. Management expects to announce the plan within the current quarter and says it is on the fast track.
Purohit: "we should be able to announce the plan within this quarter only, but yes, I think it's on the fast track."
Operational Risks & Watchpoints
- Pondicherry fire contained: A recent fire incident affected two blocks out of 76 blocks at the Pondicherry facility. Initial assessment is done, an investigation report is expected within the week, and prima facie there will be some impact but no significant impact. The quantum of impact is still to be determined.
- Profitability timeline open-ended: No specific quarter or year was given for returning to profitability. Corrective measures have already been taken; the objective is to demonstrate strong QoQ and YoY growth and "automatically come out of the woods."
- H2 aspirations, not guidance: Management's aspiration is to deliver QoQ and YoY growth, with the objective being to fix fundamentals (utilization, product mix, market share). Growth will be a function of these measures rather than a committed trajectory.
Purohit: "Our objective is to fix the fundamentals of the company and once the utilization goes up, once we have a better utilization of other products, when our market share increases all these things, we are taking all these measures together, so automatically it will be a function."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Rights issue announcement | Plan to be announced | Within the current quarter (Q3 FY24) |
| Gross margin recovery | Return to 50% historic level consistently | Next 2–3 years |
| EBITDA margin target | Reach higher-teens level | No date; corrective steps underway |
| Ibuprofen demand stability | Stable in a range, based on customer discussions | Next 2–3 years |
| Revenue growth aspiration | Mid-teens revenue growth target | Over 2–3 years |
| Vizag full utilization (conservative case) | ₹50–60 crores minimum turnover increase, ₹20–30 crores margin addition | No date; "definitely doable on a conservative basis" |
| Debtors improvement | Good improvement expected | No date; function of business activities |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹426.4 cr, 20% QoQ and ~25% YoY growth |
| Gross margin | 44.3%, similar to Q2 FY23; value ₹189.1 cr, 25% YoY growth |
| EBITDA | 9.0%, 331 bps QoQ improvement; value ₹38.2 cr, 27% YoY growth |
| Revenue from regulated markets | 70% of total revenue |
| Gross debt | ₹972 cr as of Sep 30, reduced by ₹29 cr from Mar 23 |
| Working capital | ₹811.5 cr, ~190 days, improved ~20 days over Mar 23 |
| Vizag capacity utilization | ~50%, up from 20–25% previously |
| Vizag under recoveries | Halved in H1 FY24, down to ~₹10 cr from ~₹40 cr |
| Vizag revenue | ~₹33 cr in Q2, ~₹50–60 cr in H1 FY24 |
| New products revenue contribution | 5–10% of total revenue |
| R&D market extensions filed | 11 filed for 10 existing products in H1 FY24 |
| Other expenses YoY increase | ~₹20 cr, partly due to lower Vizag utilization earlier |